GSK Reports Wednesday With Options Traders Turning Bullish

GSK plc, the British pharmaceutical group, reports third-quarter results on Wednesday with options positioning at its most call-heavy in nearly a year, a striking shift given the stock's flat month.

Options traders have turned unusually bullish into the print. The put/call ratio has dropped to 0.54, more than two standard deviations below its 20-day average of 0.63, and close to the lowest reading of the past 52 weeks. That level of call dominance is rare for a $100 billion pharma name and suggests investors are positioning for a positive surprise rather than hedging against disappointment. The stock closed at $50.75, up about 2.5% on the week after slipping less than 1% on Friday, leaving it essentially flat over the past month.

Short sellers are not pressing the bear case. Estimated short interest has fallen around 2.6% over the past week and nearly 6% over the past month. Borrowing costs are low at around 0.49% and have eased roughly 10% from a month ago. Availability is ample at 272%, meaning there are nearly three shares available to borrow for every one already shorted. None of this points to a market that sees meaningful downside risk from the print.

The analyst backdrop is harder to read cleanly. Citigroup reinstated coverage with a Neutral rating in July, while Barclays downgraded to Underweight in January. Jefferies moved to Buy in late October 2025. The consensus picture is mixed, with no clear directional push from major firms in the weeks immediately before this event. On valuation, GSK trades at roughly 9.7 times earnings with an EV/EBITDA of 13.7, both little changed over the past month. The earnings yield ranks in the 93rd percentile of the ORTEX universe, a signal that the stock is cheap on income relative to peers even after the recent gains. A previous note flagged that GSK has been a year-to-date laggard against AstraZeneca and Sanofi, a gap the Q3 print could either close or cement.

One piece of real-economy data adds a cautionary note. The Centers for Medicare and Medicaid Services Medicaid drug utilisation dataset shows GSK's Medicaid units reimbursed have fallen for four consecutive quarters, reaching roughly 50.8 million units in the period ending January 2026. Medicaid prescriptions tell the same story, declining for four straight quarters to around 1.5 million. The dataset has not been measured as a leading indicator for GSK's reported figures, so these trends are context rather than a signal about the print's direction. But the streak is long enough to be a feature of the Q3 debate.

The Wednesday release will test whether GSK's operational momentum in oncology and vaccines, flagged in a recent note after Q3 beat expectations by 8% on underlying operating profit, is enough to justify the call-heavy positioning and close the performance gap with European pharma peers.